Shares in ADC Therapeutics fell sharply after the company said it had suspended a trial of Zynlonta in previously untreated diffuse large B-cell lymphoma (DLBCL) patients
Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics' lymphoma therapy Zynlonta – approved in the US last year – in Europe and other inte
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in relapsed/refractory